Journal of the American College of Cardiology
Volume 52, Issue 25, 16–23 December 2008, Pages 2119-2126
State-of-the-Art PaperInterpreting the Results of Cost-Effectiveness Studies
Under an Elsevier user license
open archive
Key Words
costs
cost-effectiveness
quality of life
Abbreviations and Acronyms
CE
cost-effectiveness
CRT-D
cardiac resynchronization therapy defibrillator
CRT-P
cardiac resynchronization therapy pacemaker
DES
drug-eluting stent(s)
iCER
incremental cost-effectiveness ratio
QALY
quality-adjusted life year
Cited by (0)
Dr. Cohen reports grant support from Eli Lilly, Cordis, Boston Scientific, Bristol-Myers Squibb/Sanofi, The Medicines Company, and Edwards Lifesciences, as well as consulting fees from Medtronic. Dr. Reynolds is supported by grant K23 HL077171 from the National Heart, Lung, and Blood Institute and also reports grant support from Edwards Lifesciences and consulting fees from Biosense Webster, and Sanofi-Aventis.
Copyright © 2008 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.